A Look At NioCorp Developments (NasdaqGM:NB) Valuation After The Traxys Elk Creek Offtake Agreement News

NioCorp Developments (NasdaqGM:NB) recently announced a non binding term sheet with Traxys North America LLC that outlines an extensive marketing and offtake framework for critical minerals from its Elk Creek Project.

See our latest analysis for NioCorp Developments.

The Traxys term sheet arrives after a sharp shift in sentiment, with the share price up 18.44% in the last day and a 1 year total shareholder return of 55.94% despite a weaker 90 day share price return. Recent momentum appears to be rebuilding after a softer patch.

If this kind of critical minerals story has your attention, it can be useful to see what else is out there in the space and compare potential opportunities using our rare earths stock screener, starting with 30 best rare earth metal stocks

With the stock up strongly over the past year and trading at $5.91 compared with an analyst price target of $11.18, the key question is whether NioCorp remains undervalued or if the market is already pricing in future growth.

Advertisement

Preferred Price to Book Multiple of 2.7x: Is It Justified?

On a P/B basis, NioCorp trades at 2.7x, which sits below both its direct peer average of 9.5x and the broader US metals and mining average of 3x.

The P/B ratio compares the company’s market value to the book value of its net assets. This can be a useful reference point for asset heavy businesses with limited current earnings. For a pre revenue, loss making developer like NioCorp, this tends to reflect how much investors are willing to pay today for its Elk Creek project and other assets relative to their current accounting value.

Given NioCorp’s lack of meaningful revenue, current net loss of $56.108m and the fact that earnings have declined by 31.3% per year over the past 5 years, the relatively low P/B multiple indicates the market is assigning a more conservative price tag than peers that already have stronger earnings profiles. At the same time, the P/B level still sits quite close to the wider industry average, which shows investors are not heavily discounting it compared with other US metals and mining names.

Against the sector, the contrast is clear. Direct peers on average trade at a P/B of 9.5x, more than three times NioCorp’s 2.7x, while the broader US metals and mining group stands at 3x. That gap to peers points to a materially lower valuation being applied to NioCorp’s balance sheet, even though it is roughly in line with the industry overall.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book ratio of 2.7x (UNDERVALUED).

However, you still need to weigh the ongoing net loss of $56.108m and the lack of revenue. Both factors increase funding risk and execution uncertainty.

Find out about the key risks to this NioCorp Developments narrative.

Next Steps

If the combination of cautious pricing and project potential leaves you uncertain, do not wait too long to review the numbers yourself and stress test the thesis against the 4 important warning signs.

Looking for more investment ideas?

If NioCorp has caught your eye, do not stop here. Broaden your watchlist with other focused ideas that could better match your risk and income preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if NioCorp Developments might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:NB

NioCorp Developments

Engages in the exploration and development of mineral deposits in North America.

Flawless balance sheet with slight risk.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5360.5% undervalued
136 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.1% undervalued
20 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.315.7% undervalued
11 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2454.2% undervalued
31 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

QU
QuanD
AMD logo
QuanD on Advanced Micro Devices ·

Gaining Ground on Nvidia

Fair Value:US$274.3162.4% overvalued
42 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Significant headwinds will temper expectations for FY2027

Fair Value:JP¥2.28k37.2% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
UNCY logo
kapirey on Unicycive Therapeutics ·

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

Fair Value:US$9.177.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8589.8% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.226.0% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74016.7% undervalued
37 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative